Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Clinical Trials

Potential treatments for macular degeneration must successfully complete human clinical trials before seeking approval by the U.S. Food and Drug Administration.

Information about clinical trials for the United States as well as clinical trials occurring globally are available at www.clinicaltrials.gov.

Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program

August 13, 2015

MENLO PARK, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today reported financial results for the second quarter ended June 30, 2015.

Read More

Read All Avalanche News